The retinoblastoma treatment market is projected to grow from approximately USD 2.5 billion in 2023 to around USD 3.8–4.1 billion by 2033, driven by earlier genetic screening, advanced intra‑arterial chemotherapy approaches, and increasing pediatric oncology infrastructure globally. https://www.datamintelligence.com/research-report/retinoblastoma-market